Study Finds Paxlovid, Molnupiravir Reduce Omicron Hospitalization, Mortality

Researchers said that both oral antiviral drugs can be used to treat nonhospitalized patients at high risk of progressing to severe COVID-19.

A Pfizer technician handles the company's COVID-19 pill, known as Paxlovid, in a file photograph. Pfizer via AP

A recent study has shown that both ritonavir-boosted nirmatrelvir, marketed as Paxlovid, and molnupiravir could reduce mortality and hospitalization among patients infected with Omicron variants.

The study, published in the journal JAMA Network on Sept. 21, found that both oral antiviral drugs can be used to treat non-hospitalized patients who are at high risk of progressing to severe COVID-19.